INBRX-101 is a recombinant human AAT-Fc fusion protein designed to replace the enzyme that is deficient in AATD and offer less frequent dosing than current therapies for the disease, based on ...

We have identified and advanced a focused set of additional diseases and approaches that meet the same criteria. One such example is alpha-1 antitrypsin deficiency (AATD), which in many ways is ...

liver disease, or both, related to AATD. Per the company, approximately 200,000 individuals in the United States and EU have AATD due to the SERPINA1 Z mutation. Current treatments are limited to ...

Our goal was to characterize the unique effects of COPD secondary to AATD on liver disease and gene expression. A subcohort of AATD individuals with COPD (n = 33) and AATD individuals without COPD ...

Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD). BioWorld Science ...

The heart of the purchase is a protein drug, in Phase 2 trials, designed to treat α1-antitrypsin deficiency (AATD), a genetic disorder that leads to lung and liver diseases similar to cirrhosis ...

Mereo BioPharma targets osteogenesis imperfecta market growth with setrusumab. Discover why MREO stock is well-positioned for ...

Korro Bio's leading program, KRRO-110, targets alpha-1 antitrypsin deficiency (AATD), a rare pulmonary disease that affects approximately 70,000 patients in the United States. The analyst from ...